RISFAX March 20, 2019
日本語- Gilead president Hermans: Standalone expansion in the HIV field is a “strategic decision”
- Chugai Pharmaceutical and Miraca HD to form business partnership for cancer genetic mutation analysis program
- Osaka Prefecture willing to develop regional formulary at the panel on generics
- Revision of Precautions for Use: TEN and SJS added to serious side effects of “TAKECAB”
- Ministry of Health, Labor and Welfare (MHLW): “Hereditary fructose intolerance” added for careful administration of injectables containing SORBITOL and fructose
- Ono Pharmaceutical submits supplemental application of KYPRORIS for additional dosage and administration of once weekly
- Survey by the panel on generics: Young patients, “Didn’t get as cheap as expected”
- Government: Three MHLW-submitted bills such as on PMD Law amendment approved by the Cabinet
- Liberal Democratic Party Special Mission Committee for the Promotion of Data Health working group (WG): Distribution for remote medication guidance explained by ATOL, etc.
- Daiichi Sankyo: Edoxaban meets primary endpoints in patients undergoing catheter ablation
- s.maX: RUPAFIN ranks at the top, TALIGE among the top tier